May 08, 2017

Exelixis

We feel like a Sitting Duck on the markets.

“It’s waiting that helps you as an investor, and a lot of people just can’t stand to wait.” – Charlie Munger
EXEL (ISIN: US30161Q1040)

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer.       

Market: Nasdaq

http://www.exelixis.com


Gain over the last quarter: +7.1 % 

Fair value: $ 32.00
Discount: 48%
Average yearly return: 100%
TOP performer

On May 2, 2017 Exelixis reported first-quarter earnings, posting something many biotechs never achieve: profitability on an operating basis.